Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Novel therapies in the future of CLL treatment

Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James’s University Hospital Leeds, Leeds, UK, provides us an insight into the future of treatments for chronic lymphocytic leukemia (CLL), namely the combinations of novel agents such as ibrutinib and venetoclax with chemotherapy, CAR T-cells and next-generation BTK inhibitors and other novel agents that may exert less toxicity on patients compared to previous drugs. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.